Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis

Journal of Neuroimmunology

Volumn 151, Issue 1-2, 2004, Pages 55-65

  Cavaletti, G ^a,b   Cavalletti, E ^c   Crippa, L ^c   Di Luccio, E ^c   Oggioni, N ^c   Mazzanti, B ^d   Biagioli, T ^d   Sala, F ^c   Sala, V ^c   Frigo, M ^b   Rota, S ^a   Tagliabue, E ^a   Stanzani, L ^a   Galbiati, S ^a   Rigolio, R ^a   Zoia, C ^a   Tredici, G ^a   Perseghin, P ^b   Dassi, M ^b   Riccio, P ^e   Lolli, F ^d   more..

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c Cell Therapeutics Inc (Europe)   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF BASILICATA   (Italy)

Author keywords

Experimental allergic encephalomyelitis; Mitoxantrone; Pathology; Pixantrone; Rat

Indexed keywords

ANTIGEN; BBR 2778; IMMUNOSUPPRESSIVE AGENT; MITOGENIC AGENT; MITOXANTRONE; PIXANTRONE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BLOOD CELL; CARDIOTOXICITY; CELL PROLIFERATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECURRENT DISEASE; RODENT;

ACUTE DISEASE; ANIMALS; CELL DIVISION; CELLS, CULTURED; CHRONIC DISEASE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOQUINOLINES; LYMPHOCYTE COUNT; MITOXANTRONE; RATS; T-LYMPHOCYTES;

EID: 2442484708     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.02.008     Document Type: Article

References (21)

1. Alderton P.M., Gross J., Green M.D. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 52:1992;194-201
2. Avasarala J.R., Cross A.H., Clifford D.B., Singer B.A., Siegel B.A., Abbey E.E. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult. Scler. 9:2003;59-62
3. Beggiolin G., Crippa L., Menta E., Manzotti C., Cavalletti E., Pezzoni G., Torriani D., Randisi E., Cavagnoli R., Sala F., Giuliani F.C., Spinelli S. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori. 87:2001;407-416
4. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F., Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating: a new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis. N. Engl. J. Med. 349:2003;126
5. Bertazzoli C., Bellini O., Magrini U., Tosana M.G. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep. 63:1979;1877-1883
6. Borchmann P., Schnell R., Knippertz R., Staak J.O., Camboni G.M., Bernareggi A., Hubel K., Staib P., Schulz A., Diehl V., Engert A. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann. Oncol. 12:2001;661-667
7. Borchmann P., Morshhauser F., Schnell R., Harousseau J.G.C., Rudolph C., Wihlhelm M., Derigs H., Kutz K., Leynadier D., Verdi E., Camboni G., Barbieri P. A phase-II study of the aza-anthracenedione BBR 2778 in patients with relapsed aggressive non-Hodgkin lymphoma. Ann. Oncol. 13(Suppl. 2):2002;83. (Abstract)
8. Dawson L.K., Jodrell D.I., Bowman A., Rye R., Byrne B., Bernareggi A., Camboni G., Smyth J.F. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur. J. Cancer. 36:2000;2353-2359
9. Deibler G.E., Martenson R.E., Kies M.W. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 2:1972;139-165
10. Dubois B., Gonsette R., Dillen C., Billaiu A. Efficacy of a novel non cardiotoxic Aza-anthracenedione (BBR 2778) in acute experimental autoimmune encephalomyelitis. Mult. Scler. 7:2001;S20. (Abstract)
11. Edan G., Brochet B., Brassat D., Clanet M., Clavelou P., Confavreux C., Debouverie M., Heinzleff O., Lebrun C., Lubetzki C., Pelletier J., Madigand M., Rumbach L., Leray E. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients. Neurology. 58:2002;A168
12. Fetzer U., Lufen H., Mauch E., Kornhuber H. Changes in subsets and surface markers distribution of lymphocytes in MS patients during immunotherapy. Weitholter H. Current Concepts in Multiple Sclerosis. vol. 960:1981;281-284 Elsevier, Amsterdam
13. Fidler J.M., DeJoy S.Q., Gibbons J.J. Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone: I. Suppression of B lymphocyte function. J. Immunol. 137:1986;727-732
14. Fidler J.M., DeJoy S.Q., Smith F.R. III, Gibbons J.J. Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone: II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J. Immunol. 136:1986;2747-2754
15. Gbadamosi J., Buhmann C., Tessmer W., Moench A., Haag F., Heesen C. Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur. Neurol. 49:2003;137-141
16. Gbadamosi J., Munchau A., Weiller C., Schafer H. Severe heart failure in a young multiple sclerosis patient. J. Neurol. 250:2003;241-242
17. Ghalie R.G., Mauch E., Edan G., Hartung H.P., Gonsette R.E., Eisenmann S., Le Page E., Butine M.D., Goodkin D.E. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult. Scler. 8:2002;441-445
18. Gonsette R.E. Mitoxantrone immunotherapy in multiple sclerosis. Mult. Scler. 1:1996;329-332
19. Gonsette R.E. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J. Neurol. Sci. 206:2003;203-208
20. Hartung H.P., Gonsette R., Konig N., Kwiecinski H., Guseo A., Morrissey S.P., Krapf H., Zwingers T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 360:2002;2018-2025
21. Lolli F., Liuzzi G.M., Vergelli M., Massacesi L., Ballerini C., Amaducci L., Riccio P. Antibodies specific for the lipid-bound form of myelin basic protein during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 44:1993;69-75